Biogen Inc BIIB:NASDAQ (Common Stock)

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
318.78 1.78   0.56%2,261,4584.8M
Market data is delayed by at least 20 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 7/31/2015

Latest News Headlines for Biogen Inc

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Biogen, Inc.

NEW YORK, July 28, 2015 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Biogen, Inc. ("Biogen" or the "Company") (NasdaqGS: BIIB -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.

Biogen Enters Collaboration with the Parkinson's Institute and Clinical Center

Collaboration aims to enhance disease understanding and increase the pace of discovery of new therapeutics CAMBRIDGE, Mass. & SUNNYVALE, Calif.--(BUSINESS WIRE)--July 27, 2015-- Biogen (NASDAQ:BIIB) and the Parkinson's Institute and Clinical Center today announced the formation of a strategic alliance focused on enhancing the understanding of the underlying biology of Parkinson's disease (PD) and the creation of novel tools and programs that could accelerate research and the development of new PD treatments. The agreement will combine the unique clinical expertise and data of the Institute with Biogen's focus on neurodegenerative disease and approach to clinical development.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation of Biogen Inc. and Its Board of Directors in Connection with Possible Violations of Federal Securities Laws

NEW YORK--(BUSINESS WIRE)--July 24, 2015-- Levi & Korsinsky is investigating the Board of Directors of Biogen Inc. ("Biogen" or the "Company") (NASDAQGS: BIIB) for possible violations of federal securities laws. The investigation concerns whether Biogen and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On Friday, July 24, 2015, prior to the opening of the market, Biogen reported its second quarter 2015 financial results. Among other things, the Company lowered its prior revenue guidance based largely on lowered expectations for the growth of its main drug, TECFIDERA. On the announcement of this news, the share price of Biogen stock plunged more than $59, or approximately 15%, during premarket trading on July 24, 2015 -- from a prior day's closing price of $385.05 to the opening price of $326.01. To obtain additional information, go to:

View more recent headlines

Peers Information HelpBIIB Biogen Inc vs. Peers

-6.09%
BIIB
Biogen Inc
-4.17%
Johnson & Johnson
Pfizer Inc.
15.76%
Merck & Co., Inc.
3.82%
AbbVie Inc
6.98%
BIIB
Biogen Inc
0.00%
Johnson & Johnson
2.99%
Pfizer Inc.
3.11%
Merck & Co., Inc.
3.05%
AbbVie Inc
2.91%
BIIB
Biogen Inc
0.56%
Johnson & Johnson
0.37%
Pfizer Inc.
0.92%
Merck & Co., Inc.
0.75%
-0.21%
AbbVie Inc
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company's marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN (rituximab), which is a monoclonal antibody for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.

https://www.biogen.com/

Loading...

collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open319.57
Previous Close317.00
Day High322.35
Day Low312.70
52 Week High3/20/2015 | 480.18
52 Week Low10/22/2014 | 290.85
% Off 52 Week High(33.61)%
% Off 52 Week Low9.60%
Beta (5 Yr)0.91
Volatility Avg7/31/2015 | 39.27
10-Day Avg. Volume4,824,081
Market data is delayed by at least 20 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)6/30/2015 | 14.78
P/E Ratio6/30/2015 | 21.6
Market CapLarge Cap | 75.0B
Shares Outstanding235.17M
Float234.9M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Ex-Date--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short2.60M
Short Ratio1.7
Short % of Float1.11%
As of 7/15/2015